Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Notice Regarding Change in fair value of contingent consideration and Differences Between Consolidated Financial Forecasts and Actual Results
Presentation Material for Information Meeting (FY2024)
Supplementary Documents (FY2024)
Financial Results (FY2024)
Astellas Pharma, Last Fiscal Year's Net Income Unexpectedly Increases, 2.6 times Increase in Net Income for The Current Fiscal Year, Dividend Raised by 4 yen
Presentation Material for Sustainability Meeting (FY2024)
U.S. FDA Approves Expanded Label for Astellas’ IZERVAY(avacincaptad pegol intravitreal solution) for Geographic Atrophy
Recording of Extraordinary Losses in Non-consolidated Financial Results(J-GAAP)
Presentation Material for Information Meeting (Q3 YTD/FY2024)
Supplementary Documents (Q3 YTD/FY2024)
Financial Results (Q3 YTD/FY2024)
Astellas Pharma, Apr-Dec (Cumulative 3Q) Net Income Turns to Loss, Oct-Dec Net Income Turns to Loss
Notice Regarding Progress in Core Business, Impairment Loss and Revision of Financial Forecasts for FY2024
Astellas Pharma, The Current Fiscal Year Net Income Revised Downward to an Unexpected 18% Decrease
U.S. FDA Confirms Class 1 Resubmission of the Supplemental New Drug Application for IZERVAY(avacincaptad pegol intravitreal solution) for Geograph
Corporate Governance Report
Astellas Provides Update on IZERVAY (avacincaptad pegol intravitreal solution) Supplemental New Drug Application
Astellas Pharma Inc., The Current Fiscal Year Net Income Revised Upward by 67%
Notice Regarding Foreign Exchange Loss
Presentation Material for Information Meeting (Q2 YTD/FY2024)